XBiotech Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from XBiotech Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-45.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 71% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -39%In 3 years sales changed by -100% while total assets changed by -39%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
XBiotech Inc. made a loss over the last year. XBiotech Inc. owes $0.04 for every $1 it owns. XBiotech Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossXBiotech Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.46The share price is 0.46 times XBiotech Inc.'s book value per share, lower than 92% of Healthcare companies in United States.
Market cap
$59 MThe total market value of all of XBiotech Inc.'s shares at today's price (share price × number of shares), smaller than 72% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$128 MWhat XBiotech Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.21Net worth divided by the number of shares. The share price of $1.93 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
-29.9%XBiotech Inc. lost 29.9% of its shareholders' money over the last year, higher than 60% of Healthcare companies in United States.
Owes vs Owns
0.04×XBiotech Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Dividend yield
NoneXBiotech Inc. does not currently pay a dividend.
Profit growth
LossXBiotech Inc. made a loss in each of the last two years.
Interest cover
Not coveredXBiotech Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For XBiotech Inc.: $59 M ÷ $128 M (30 Jun 2026) = 0.5.
What is XBiotech Inc.'s return on equity?
XBiotech Inc. lost 29.9% of its shareholders' money over the last year, higher than 60% of Healthcare companies in United States.
How much does XBiotech Inc. owe compared with what it owns?
XBiotech Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Does XBiotech Inc. pay a dividend?
No. XBiotech Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.